🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Split 2:1 del 22/11/1999

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.656.089

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 3 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
12/05/2015 0,7900 USD
10/02/2015 0,7900 USD
10/11/2014 0,6100 USD
12/08/2014 0,6100 USD
13/05/2014 0,6100 USD
11/02/2014 0,6100 USD
12/11/2013 0,4700 USD
14/08/2013 0,4700 USD
14/05/2013 0,4700 USD
11/02/2013 0,4700 USD
13/11/2012 0,3600 USD
14/08/2012 0,3600 USD
14/05/2012 0,3600 USD
13/02/2012 0,3600 USD
15/11/2011 0,2800 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/03/2011 51,64 52,54 51,46 52,37 +1,91% 2,09% 6.527.500
02/03/2011 51,74 51,91 51,34 51,39 -1,00% 1,10% 5.437.400
01/03/2011 52,17 52,49 51,74 51,91 +1,13% 1,44% 6.668.500
28/02/2011 52,38 52,67 51,31 51,33 -1,78% 2,60% 8.054.800
25/02/2011 51,18 52,37 51,05 52,26 +2,57% 2,58% 7.791.100
24/02/2011 51,07 51,24 50,61 50,95 -0,23% 1,23% 8.606.600
23/02/2011 51,89 52,18 51,07 51,07 -1,56% 2,14% 8.135.500
22/02/2011 51,97 52,54 51,62 51,88 -0,69% 1,77% 6.473.900
18/02/2011 52,26 52,73 52,02 52,24 -0,32% 1,36% 9.877.900
17/02/2011 52,69 53,19 52,37 52,41 -1,02% 1,56% 8.918.600
16/02/2011 53,34 53,43 52,36 52,95 -1,65% 2,01% 11.461.500
15/02/2011 53,63 53,94 53,31 53,84 -0,04% 1,17% 5.143.000
14/02/2011 53,61 54,08 53,34 53,86 +0,22% 1,38% 5.412.600
11/02/2011 54,11 54,11 53,55 53,74 -0,98% 1,03% 6.896.900
10/02/2011 54,33 54,80 54,00 54,27 -0,29% 1,47% 4.522.300
09/02/2011 54,73 55,00 54,31 54,43 -0,93% 1,26% 4.502.700
08/02/2011 54,76 55,16 54,63 54,94 +0,11% 0,97% 3.399.300
07/02/2011 55,23 55,33 54,76 54,88 -0,58% 1,03% 3.861.900
04/02/2011 55,62 55,62 54,74 55,20 -0,45% 1,58% 4.569.900
03/02/2011 55,27 55,64 55,00 55,45 -0,32% 1,16% 4.227.000
02/02/2011 55,14 55,65 54,79 55,63 -0,14% 1,56% 5.353.400
01/02/2011 55,23 55,88 55,11 55,71 +1,14% 1,39% 5.615.800
31/01/2011 55,22 55,46 54,85 55,08 -0,38% 1,10% 6.021.300
28/01/2011 56,61 56,61 55,11 55,29 -2,11% 2,65% 6.928.300
27/01/2011 56,46 56,87 56,06 56,48 +0,00% 1,43% 4.686.000
26/01/2011 57,27 57,47 56,32 56,48 -1,19% 2,01% 6.833.600
25/01/2011 56,91 58,19 56,74 57,16 -0,23% 2,55% 8.944.000
24/01/2011 57,06 57,87 56,81 57,29 +0,56% 1,86% 5.647.800
21/01/2011 57,41 57,41 56,74 56,97 -0,59% 1,17% 6.032.900
20/01/2011 56,78 57,65 56,68 57,31 +0,58% 1,71% 6.313.600